PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT07868835 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT07931495 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07931547 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07517042 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07850063 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07775846 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07924553 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05555589 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07668336 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07843485 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07843498 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07913685 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT05958342 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07850050 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04466566 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07768813 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT04501861 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07221591 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07855900 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07897305 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06593392 at 2026-11-15T21:56:33.343Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02000089 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT07633600 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT02974907 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-10-21, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT06937749 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT06976619 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT03689699 at 2026-11-15T21:52:09.579Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT07861100 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide.
PeptideScanner retained ClinicalTrials.gov record NCT07846488 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07843862 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.